News | Women's Health | March 10, 2022

Players will be screened in Indian Wells on Hologic’s state-of-the-art DXA technology, providing valuable health and performance insights

Hologic and the WTA kicked off a multi-year partnership this week with their first onsite activities at the BNP Paribas Open in Indian Wells, launching a joint vision to achieve greater wellness and equality for women.

March 10, 2022 — Hologic and the WTA kicked off a multi-year partnership this week with their first onsite activities at the BNP Paribas Open in Indian Wells, launching a joint vision to achieve greater wellness and equality for women. The Hologic WTA Tour was announced last week when medical technology leader Hologic became the title sponsor for the WTA, the global leader in women’s professional sports.

In alignment with the WTA’s commitment to making athlete health and wellness a top priority – and Hologic’s focus on improving women’s health through early detection, diagnosis, and treatment – the partnership will allow players to receive expanded and specialized screenings.

In a first for WTA athletes, those competing in the BNP Paribas Open will have the opportunity to undergo an evaluation with Hologic’s Horizon DXA system. The system provides detailed analysis of bone density and body composition by looking at multiple factors and segmented data on different parts of the body.

“The DXA analysis gives players and their teams valuable insights about body composition and bone health that can be used to help inform health decisions as well as training and performance strategies,” said Dr. Susan Harvey, Chief Medical Officer for Hologic’s Breast and Skeletal Health Solutions Division. “We’re thrilled to join forces with the WTA to provide elite athletes with this world-class health and performance technology.”

The DXA scan will be added to the robust health screenings that the WTA already provides for players, including evaluations with specialists across dermatology, cardiology, orthopedics, internal medicine, nutrition and hydration, and mental health.

WTA athletes will have access to physical exams at the tournament grounds from March 7–10. With support from Hologic, the WTA will now increase its frequency of preventive healthcare screenings to empower the organizations’ joint mission of championing women and making their health a top priority.

Kathleen Stroia, WTA SVP Performance Health, stated, “We are excited to welcome the Hologic team and its leading medical technology to the WTA’s players health and wellness experience. This is just the beginning of what we can achieve through this innovative partnership. Not only does this elevate the players’ immediate physical healthcare, but it also amplifies the greater mission we share for promoting healthy practices and preventive care, which positions us to globally champion women’s health.”

This is one example of what the two organizations hope to accomplish together – providing broader opportunities for advocacy and building awareness about screenings and early detection.

ACEing Cancer

The Hologic-WTA collaboration also will come to life this week through WTA Charities’ ACEing Cancer program. Beginning at the BNP Paribas Open and continuing at all WTA tournaments throughout the season, Hologic will make contributions to WTA Charities’ ACEing Cancer program, an initiative designed to raise awareness and proceeds towards the fight against women’s cancers. WTA athletes and legends of the game will participate in various ACEing Cancer activities to help raise awareness of the need for early detection, diagnosis, and treatment. The public can join the cause as well. Learn more about ACEing Cancer.

The Hologic-WTA partnership begins at a pivotal moment when health screenings are down for women across the world because of the COVID pandemic. It’s more important than ever that women prioritize their health – and one way to do that is through an annual Well Woman visit. To learn more about the Well Woman exam, visit ScreeningsForHer.com.

For more information: www.hologic.com


Related Content

News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
Subscribe Now